|本期目录/Table of Contents|

[1]李亮,曹昌魁,聂时南.小剂量氢化可的松治疗严重脓毒症患者的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2016,18(05):455-457,482.[doi:10.3969/j.issn.1672-271X.2016.05.002]
 LI Liang,CAO Chang-kui,NIE Shi-nan..A clinical research of low-dose hydrocortisone treatment in severe sepsis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(05):455-457,482.[doi:10.3969/j.issn.1672-271X.2016.05.002]
点击复制

小剂量氢化可的松治疗严重脓毒症患者的疗效观察()

《医学研究与战创伤救治》(原医学研究生学报)[ISSN:1672-271X/CN:32-1713/R]

卷:
第18卷
期数:
2016年05期
页码:
455-457,482
栏目:
出版日期:
2016-09-20

文章信息/Info

Title:
A clinical research of low-dose hydrocortisone treatment in severe sepsis
作者:
李亮曹昌魁聂时南
210002江苏南京,南京军区南京总医院急救医学科
Author(s):
LI Liang CAO Chang-kui NIE Shi-nan.
Department of Emergency Medicine, Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing, Jiangsu 210002, China
关键词:
严重脓毒症氢化可的松预后炎症因子
Keywords:
severe sepsis hydrocortisone prognosis inflammatory factor
分类号:
R459.7
DOI:
10.3969/j.issn.1672-271X.2016.05.002
文献标志码:
A
摘要:
目的 观察小剂量氢化可的松对严重脓毒症患者预后和炎症反应的影响。方法 按照是否进行小剂量氢化可的松治疗将符合入选标准的患者随机分为治疗组和对照组,对两组患者进行急性生理与慢性健康(APACHE Ⅱ)评分,治疗组在常规治疗基础上加用小剂量氢化可的松治疗。比较两组患者死亡率、血管活性药物使用天数、住EICU和总住院时间及0、1、3、5 d血清白介素-6(interleukin,IL-6)浓度。结果 共入选治疗组56例,对照组50例。两组患者入院时的年龄、性别和APACHE Ⅱ评分差异无统计学意义,治疗后两组患者的死亡率、血管活性药物使用天数、住急诊监护病房(EICU)时间和总住院时间差异无统计学意义(P>0.05)。治疗组患者的IL-6水平明显低于对照组。结论 小剂量氢化可的松治疗能减轻严重脓毒症患者的炎症反应,但不能明显改善严重脓毒症患者的预后。
Abstract:
Objective To research the effect of low-dose hydrocortisone treatment on prognosis and inflammation of severe sepsis patient. Methods Severe sepsis patient who met the inclusion criteria were randomly divided into treatment group and control group. The two groups were evaluated with APACHE Ⅱ and given routine therapy. The treatment group was treated with additional low-dose hydrocortisone. To compare mortality, time of using of vasoactive agent, emergency intensive care unit length of stay, hospital length of stay and the concentration of interleukin-6 at 0,1,3,5 days between the two groups. Results 56 patients were enrolled in treatment group and 50 in control group. There was no significant difference of age, gender and mean APACHE Ⅱ scores in the two groups. After treatment, there was no significant difference of mortality, time of using of vasoactive agent, emergency intensive care unit length of stay, hospital length of stay and the concentration of interleukin-6 at 0,1,3,5 days in the two groups. Concentration of interleukin-6 of treatment group was decreased compared to the control group. Conclusion Low-dose hydrocortisone treatment can reduce inflammatory response in patients with severe sepsis. No definitive improvement in outcomes can be attributable to adjunctive low-dose hydrocortisone therapy.

参考文献/References:

[1]Zahar JR, Timsit JF, Garrouste-Orgeas M, et al. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality[J]. Crit Care Med, 2011, 39(8): 1886-1895.
[2]Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013, 39(2): 165-228.
[3]廖延年,黄骞,黎介寿.晚期糖基化终末产物受体在腹腔感染脓毒症中的研究进展[J].医学研究生学报,2015,28(6):656-660.
[4]刘文飞,朱振新,颜荣林.AMPK/mTOR通路参与脓毒症亮氨酸抵抗的研究进展[J].医学研究生学报,2014,27(12):1311-1314.
[5]Albert SG, Ariyan S, Rather A. The effect of etomidate on adrenal function in critical illness: a systematic review[J]. Intensive Care Med, 2011, 37(6): 901-910.
[6]刘瑜,方放,黄方. 糖皮质激素受体基因多态性与脓毒症临床转归的相关性研究[J]. 东南国防医药,2015, 17(6):575-578.
[7]Angus DC, van der Poll T. Severe sepsis and septic shock[J]. New England J Med, 2013, 369(9): 840-851.
[8]Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review[J]. JAMA, 2009, 301(22): 2362-2375.
[9]Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study[J]. Am J Resp Crit Care Mede, 2003, 167(4): 512-520.
[10]盛志勇, 姚咏明. 努力提高脓毒症的认识水平[J]. 感染、炎症、修复, 2003, 4(1): 3.
[11]Levy B, Collin S, Sennoun N, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside[M]. Appl Physiol Intensive Care Med, 2012: 251-261.
[12]Gustot T. Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response[J]. Curr Opin Crit Care, 2011, 17(2): 153-159.
[13]李林, 赵亚伟. APACHEⅡ 评分在外科 ICU 中的应用[J]. 中国危重病急救医学, 2002, 14(5): 308-310.
[14]高戈, 冯喆, 常志刚,等. 2012 国际严重脓毒症及脓毒性休克诊疗指南[J]. 中华危重病急救医学, 2013, 25(8): 501-505.
[15]Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis[J]. Virulence, 2014, 5(1): 4-11.
[16]马朋林. 认识与挑战: 脓毒症流行病学变化的启示[J]. 解放军医学杂志, 2012, 37(11): 1015-1018.
[17]Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care[J]. J Antimicrob Chemother, 2011, 66(suppl 2): 33-40.
[18]Kang CI, Song JH, Chung DR, et al. Risk factors and pathogenic significance of severe sepsis and septic shock in 2286 patients with gram-negative bacteremia[J]. J Infect, 2011, 62(1): 26-33.
[19]Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues[J]. Am Surg, 2012, 78(1): 1-8.
[20]Michalaki M, Margeli T, Tsekouras A, et al. Hypothalamic-pituitary-adrenal axis response to the severity of illness in non-critically ill patients: does relative corticosteroid insufficiency exist?[J]. Eur J Endocrinol, 2010, 162(2): 341-347.
[21]Marik PE. Glucocorticoids in sepsis: dissecting facts from fiction[J]. Crit Care, 2011, 15(3): 158-163.
[22]Arabi YM, Aljumah A, Dabbagh O, et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial[J]. Canadian Med Assoc J, 2010, 182(18): 1971-1977.
[23]Barochia AV, Cui X, Vitberg D, et al. Bundled care for septic shock: an analysis of clinical trials[J]. Crit Care Med, 2010, 38(2): 668.
[24]Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, et al. The pathogenesis of sepsis[J]. Ann Rev Pathol, 2011, 6: 19-48.
[25]Krüttgen A, Rose-John S. Interleukin-6 in sepsis and capillary leakage syndrome[J]. J Interferon Cytokine Res, 2012, 32(2): 60-65.
[26]Whiteley W, Jackson C, Lewis S, et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6[J]. PLoS, 2009, 6(9): 145-151.
[27]Vouloumanou EK, Plessa E, Karageorgopoulos DE, et al. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis[J]. Intensive Care Med, 2011, 37(5): 747-762.

相似文献/References:

备注/Memo

备注/Memo:
国家自然科学基金青年基金课题(81401583);全军后勤面上项目(CNJ14L002);全军医学科技青年培育项目(13QNP038);南京军区面上项目(14MS111)作者单位:210002江苏南京,南京军区南京总医院急救医学科
更新日期/Last Update: 2016-12-09